Adalta Ltd Market Cap ($5.41 Million)
Market Cap & Net Worth: Adalta Ltd (1AD)
Adalta Ltd market cap. Adalta Ltd (AU:1AD) has a market capitalization of $5.41 Million (AU$7.65 Million) as of November 8, 2026. Listed on the AU stock exchange, this Australia-based company holds position #28328 globally and #1456 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Adalta Ltd's stock price AU$0.00 by its total outstanding shares 2549669043 (2.55 Billion). Also see cash flow conversion of Adalta Ltd for how efficiently the company converts equity into cash flow.
Adalta Ltd Market Cap History (2016–2026)
Adalta Ltd market cap history from 2016 to 2026. Data shows change from $287.57 Million to $5.41 Million (-35.46% CAGR). Check Adalta Ltd stock quote for real-time trading data and today's change.
Adalta Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Adalta Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Adalta Ltd net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
7.99x
Adalta Ltd's market cap is 7.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $287.57 Million | $738.05K | -$1.16 Million | 389.63x | N/A |
| 2017 | $422.87 Million | $1.80 Million | -$2.83 Million | 235.35x | N/A |
| 2018 | $389.13 Million | $2.02 Million | -$3.85 Million | 192.62x | N/A |
| 2019 | $201.69 Million | $3.54 Million | -$5.92 Million | 57.00x | N/A |
| 2020 | $223.34 Million | $3.85 Million | -$6.01 Million | 58.06x | N/A |
| 2021 | $144.32 Million | $3.99 Million | -$5.63 Million | 36.20x | N/A |
| 2022 | $73.97 Million | $2.76 Million | -$6.06 Million | 26.85x | N/A |
| 2023 | $43.30 Million | $3.47 Million | -$4.85 Million | 12.48x | N/A |
| 2024 | $28.86 Million | $1.74 Million | -$5.38 Million | 16.61x | N/A |
| 2025 | $5.41 Million | $677.01K | -$4.50 Million | 7.99x | N/A |
Competitor Companies of 1AD by Market Capitalization
Companies near Adalta Ltd in the global market cap rankings as of November 8, 2026. Also see balance sheet size of Adalta Ltd for a full breakdown of the balance sheet.
Key companies related to Adalta Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Adalta Ltd (2016–2026)
Market capitalization of Adalta Ltd from 2016 to today. Between 2016 and today, Adalta Ltd's market cap moved from $287.57 Million to $ 5.41 Million, with a yearly change of -35.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$5.41 Million | 0.00% |
| 2025 | AU$5.41 Million | -81.25% |
| 2024 | AU$28.86 Million | -33.33% |
| 2023 | AU$43.30 Million | -41.46% |
| 2022 | AU$73.97 Million | -48.75% |
| 2021 | AU$144.32 Million | -35.38% |
| 2020 | AU$223.34 Million | +10.73% |
| 2019 | AU$201.69 Million | -48.17% |
| 2018 | AU$389.13 Million | -7.98% |
| 2017 | AU$422.87 Million | +47.05% |
| 2016 | AU$287.57 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Adalta Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.41 Million USD |
| MoneyControl | $5.41 Million USD |
| MarketWatch | $5.41 Million USD |
| marketcap.company | $5.41 Million USD |
| Reuters | $5.41 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Adalta Ltd
AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age… Read more